Cartherics to Present at Biotech Showcase™ 2023

Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners

Melbourne, Australia, 22 December 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view Cartherics’ presentation live, and also access a recorded version. With 24×7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Dr Ian Nisbet, Chief Operating Officer will be presenting Cartherics’ technology and development program at Biotech Showcase at 2.00pm (PST) on Wednesday 11 January.

Cartherics has established a powerful allogeneic cell therapy platform. Key features include:

• Precisely engineered induced pluripotent stem cells (iPSCs)
• Proprietary CAR constructs and immunosuppressive gene knock-outs
• Proprietary manufacturing process
• Pipeline of immune cell therapies, including CAR-iNK and CAR-iT products
• Focus on solid tumors
• Substantial IP portfolio

Prof Alan Trounson, Cartherics’ CEO, stated, “We are proud to be part of the annual gathering of industry leaders and investors in San Francisco and to have the opportunity to highlight our technology platform and products at Biotech Showcase.  We look forward to constructive meetings with potential partners and investors from all over the world.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Cartherics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT CARTHERICS

Cartherics is a privately-held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered to provide enhanced function for the derived NK and other immune cells.

The Company is also developing autologous CAR-T cell therapies. These use the patient’s own immune system T-cells, which are modified to be effective against the patient’s cancer cells. CTH-001 for the treatment of CTCL is the first product candidate progressing into human clinical trials. A second candidate, CTH-004, is being developed for the treatment of ovarian cancer.

 

Follow Cartherics on Twitter at @cartherics and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.

Follow Cartherics on LinkedIn at: https://au.linkedin.com/company/cartherics-pty-ltd

 

Cartherics company contact

Dr Ian Nisbet

Cartherics

Email: nisbet@afandin.com

Phone: +61 431 709 121

 

Cartherics media contact

Dr Christine Filippis

Teraze Communications

Email: christine@teraze.com.au

Phone: +61 419 119 866